Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of mRNA-1893 Zika Vaccine
NCT04064905Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial in Zika virus infection comparing mRNA-1893 with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination, Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-Second Vaccination and 2 more. Started Jul 2019; status: completed.
02
Drugs
mRNA-1893
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT04064905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064905.